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Abstract
Anaplastic thyroid carcinoma (ATC) is a rare, aggressive malignancy, which is known to metastasize to the heart.
We report a case of a patient with ATC with metastatic involvement of the pacemaker leads within the right
atrium and right ventricle. The patient survived external beam radiation treatment to his heart, with a radiographic
response to treatment. Cardiac metastases are usually reported on autopsy; to our knowledge, this is the first
report of the successful treatment of cardiac metastases encasing the leads of a pacemaker, and of cardiac
metastases from ATCs, with a review of the pertinent literature.
Background
Anaplastic thyroid carcinoma (ATC) is a rare, aggressive
malignancy with a median survival of 6 months. Distant
metastases - usually to lungs and bone - present early in
t h ec o u r s eo fd i s e a s e[ 1 ] .A T Ci sa l s oo n eo ft h ef e w
cancers known to metastasize to the heart [2].
Secondary cardiac tumors are usually reported at
autopsy, and can involve various anatomic structures of
the heart. While cardiac metastases can be treated with
external beam radiation, cardiac toxicity remains dose-
limiting and must be taken into consideration during
radiation treatment planning for patients with poor car-
diac function and pacemaker dependence.
We report the case of a patient with ATC who pre-
sented with intraventricular metastases encasing the
electrical leads of his pacemaker. After a course of pal-
liative radiation therapy to his right atrium and ventri-
cle, the patient survived to demonstrate radiographic
response to treatment.
As cardiac metastases are increasing in incidence, we
detail the radiation methods used to treat these intracar-
diac metastases, including specific precautions taken for
the pacemaker leads within the field of radiation. To our
knowledge, this is the first report of the successful treat-
ment of cardiac metastases from from ATCs, and of
mural metastases encasing the leads of a pacemaker.
Case
The patient is an 80 year old male with a past medical
history of atrial fibrillation with sinus block with dual
chamber pacemaker placed in November 2006, and a
complicated oncologic history including breast cancer in
the 1970s treated with left-sided mastectomy and axil-
lary lymph node dissection; prostate cancer treated with
intensity modulated radiation therapy (IMRT) in 2001;
mucosal melanoma with metastases to small bowel trea-
ted with small bowel resection in 2005; and multiple
skin cancers. He was treated with a total thyroidectomy
for anaplastic thyroid carcinoma in March 2008, fol-
lowed by post-operative cisplatin-based chemo-radiation
therapy to the surgical bed and the draining lymph
n o d e s .As u b s e q u e n tl e f tl u n gn o d u l ew a st r e a t e dw i t h
thoracotomy and wedge resection in December 2008,
with documented metastatic anaplastic thyroid carci-
noma on pathology. He also received one cycle of
Abraxane and Bevacizumab in February 2009.
The patient had been asymptomatic and in his usual
state of health until July 2009 when he presented with a
2 month history of decreased exercise tolerance and
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function, leaving the patient dependent on his pace-
maker. An outpatient echocardiogram was concerning
for “intracavitary irregular densities” in the right ventri-
cle and right atrium. CT Chest with contrast revealed a
5.1 × 4.8 cm right atrial mass, with a broad base of
attachment at the right atrial posterior wall and exten-
sion into both the inferior and superior vena cava.
There was a notable displacement of pacemaker leads.
The right ventricle also demonstrated an irregular lobu-
lated 6.8 × 2.5 cm mass attached to the ventricular sep-
tum. Retrospective evaluation of a prior PET-CT from
June 2009 confirmed increased FDG uptake within the
right atrium and right ventricle.
In mid-July 2009, the patient was admitted to University
of California San Francisco Moffitt Hospital for cardiac
telemetry and management of this intracardiac mass.
Admission labs showed thrombocytopenia with platelets
ranging between 20 and 35. The differential diagnosis for
right heart masses included metastases from anaplastic
thyroid carcinoma or melanoma, a new primary cardiac
malignancy, or a thrombus.
A Fibrinogen level was within normal limits, and
hematology smears were negative for schistocytes.
A bone marrow biopsy demonstrated a normocellular
marrow for the patient’s age with mixed trilineage
hematopoesis and no evidence of lymphoma or throm-
bus. A trial of dexamethasone for suspected idiopathic
thrombocytic purpura (ITP) did not impact the
thrombocytopenia. The differential diagnosis for the
thrombocytopenia therefore remained a consumptive
coagulopathy secondary to tumor, versus tumor-
associated immune thrombocytopenia.
After careful consideration at a multi-institutional
tumor board, it was decided to treat these intracardiac
metastases with radiation therapy. A pre-treatment elec-
trophysiologic interrogation showed intermittent loss of
capture by the pacemaker, most likely secondary to
growth of the intracardiac mass. Therefore, a new pace-
maker with epicardial leads was emergently placed. Dur-
ing this procedure, biopsy of the intracardiac mass was
performed, confirming metastatic anaplastic thyroid
carcinoma.
Radiation therapy to the right atrium and part of the
right ventricle was initiated at 2.5 Gy per fraction for 15
fractions to a total dose of 37.5 Gy, with an intended
maximum dose in the tumor areas just exceeding 40 Gy
(see below) (Figure 1). Paclitaxel (50 mg/m
2) was admi-
nistered concurrently on d a y s1a n d8o fr a d i a t i o n
treatment.
During the course of his radiation treatment, the pace-
maker demonstrated full capture. A single episode of
ventricular undersensing with pacing stimuli during
T-waves was successfully addressed by the
reprogramming of the device. Transcutaneous pacer was
available during treatment should failure of the primary
pacing device occur. Echocardiograms during radiation
treatment showed that the intracardiac mass had not
increased in size. The patient required platelet transfu-
sions approximately every 48 hours, and his platelet
count held steadily around 18 to 20. Given his leukope-
nia and sepsis, Abraxane was withheld after two courses.
After discharge, the patient participated in regular
activities of daily living, including work-related meet-
ings and exercise on the treadmill, but experienced
persistent dyspnea on exertion. His pacemaker contin-
ued to demonstrate full capture without evidence of
dysfunction.
In late August 2009, less than one month after com-
pletion of treatment, a PET-CT showed decreased FDG
uptake right atrium (maximum SUV decreased from
27.9 to 7.8) and stable FDG uptake within the right ven-
tricle (Figure 2). There was some questionable uptake in
the interventricular septum, representing normal physio-
logic uptake or residual disease. Unfortunately, multiple
pulmonary and chest wall metastases were subsequently
detected.
The patient completed one additional course of pallia-
tive radiation therapy to a symptomatic left chest wall
metastasis. He died in his home two months after com-
pletion of radiation therapy.
Conclusions
I. Secondary cardiac tumors are increasing in incidence,
have various methods of spread and can affect any
anatomic region of the heart
There have been several reports of cardiac metastases in
the the literature [3,4]. Intracardiac metastases are
reported from several different primary cancers, includ-
ing melanoma, bladder[4], sarcoma[5], lung, lymphoma,
breast carcinoma[6] and cervix [7]. Cardiac metastases
from primary anaplastic thyroid carcinoma are rare - an
autopsy series has reported the rate as 0 to 2% [2].
Different routes of cancer spread have been reported,
and include hematogenous, lymphatic, and direct exten-
sion to the heart or thoracic duct [2,8]. Retrograde lym-
phatic spread is predominant. The majority of lymphatic
ducts of the heart are located on the pericardial surface,
where they coalesce adjacent to the aortic root; obstruc-
tion of these channels leading to malignant pericardial
effusions [8]. The coronary arteries are the primary con-
duits of hematogenous spread. As metastatic cancer
cells are filtered in the hepatic and pulmonary circula-
tion, metastases are unlikely to reach cardiac tissue
without metastatic disease in other organs [8].
Metastatic lesions may involve any anatomic region of
the heart, including most commonly the epicardium and
pericardium. Metastases within the cardiac chambers
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noma, cardiac metastases have been reported in the
myocardium and pericardium, as well as within the ven-
tricles [2].
II. Secondary cardiac tumors have been successfully
treated with external beam radiation
Various cardiac tumors have been reported to respond
to radiation. These include a primary cardiac sarcoma
involving right ventricular outflow track treated with a
dose 6300-7400 rads delivered with 4 fields in the
1960’s. The patient remained asymptomatic for
8 months, and autopsy identified no residual cardiac
tumor[11]. Cases of leukemic infiltration of the myocar-
dium presenting with arrhythmia [12], and interventri-
cular septum metastases with malignant pleural effusion
responding to radiation have also been reported [13]. In
a case of cardiac metastases from cervical carcinoma,
one patient with right ventricular and intraventricular
septum metastases was treated with chemoradiation
Figure 1 Radiation treatment plan for patient with right atrial and ventricular metastases from anaplastic thyroid carcinoma. The PTV
is delineated in red and received 37.50 Gy in 15 fractions, prescribed to the 87% isodose line. The median left ventricle (purple) and lateral left
ventricle (beige) were delineated as avoidance structures in this IMRT treatment plan. The 1875 cGy (18.7 Gy) isodose line is shown in light blue;
the 3500 cGy (35 Gy) isodose line, in yellow; the 3750 cGy (37.5 Gy) isodose line, in green; and the 4100 cGy (41 Gy) isodose line, in pink.
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Page 3 of 7Figure 2 PET Response to treatment of an intracardiac metastases in the R ventricle and atrium. The top panel demonstrates a PET-CT
scan of the hypermetabolic tumor mass prior to treatment on June 8 2009; the lower panel shows the tumor mass with notably decreased FDG
uptake after treatment on August 30 2009.
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and survived 7 months after presentation[10]. A recent
report also demonstrated response of intraventricular
metastases from small cell lung cancer to chemotherapy
and radiation (carboplatin and etoposide followed by
IMRT to 60 Gy to the lung mass, mediastinal LNs and
cardiac metastases). Two months after treatment, fol-
low-up PET CT showed no residual uptake in the R
ventricle or mediastinal LNs, but persistent uptake in
the lungs [14].
From these case studies, no consensus on the dose
required to control a secondary cardiac tumor can be
established. In radiosensitive tumors like lymphoma,
doses of even 20 Gy may be sufficient. However, more
radioresistant tumors may require higher doses like
4 5G yw i t hap o s s i b l ea d d i t i o n a lb o o s to f1 0t o1 5G y
for adequate control[3,15].
III. Cardiac toxicity is dose-limiting in the treatment of
cardiac metastases with external beam radiation
The dose tolerance of the pericardium is limiting[10], as
the most common manifestation of radiation-induced
heart disease (RIHD) is late-onset, chronic pericardial
disease[9]. However, any other anatomic region of the
heart can manifest cardiac damage secondary to radia-
tion, including electrical conduction system, coronary
arteries, cardiac valves, myocardium and endocardium
[9,16]. Therefore, while the dose tolerance of the whole
heart - 60 Gy if 25% of the heart is irradiated, and
45 Gy if 65% of the heart volume is irradiated [17] - is
usually taken into consideration, the different anatomic
subsites must be considered. Risk of RIHD increases
with doses > 40 Gy over 4 weeks for pericardial disease,
> 35-60 Gy for myocardial disease, > 30 Gy for valvular
disease, and > 30 Gy for coronary artery disease (espe-
cially in younger patients, with concomitant chemother-
apy), though doses as low as 5 Gy have been associated
with increased risk of coronary artery disease[9,17].
Beam energy, dose per fraction [18,19], concurrent che-
motherapy - especially with anthracyclines[16] - affect
cardiac toxicity from radiation. Most patients experien-
cing severe complications had 60% or more of their car-
diac silhouette irradiated, and risk of RIHD ranged from
6.6 to 29%. Preclinical trials suggest that cardiac gating
[20] may reduce the incidence of RIHD.
RIHD is additionally divided into early and late toxi-
city. Early toxicity, presenting within 2 to 6 months, is
most frequently pericarditis [21-23]. Radiation induced
valvular disease manifests within ten to fifteen years of
irradiation and management is similar to other types of
valvular disease[9]. In younger patients who have
received mediastinal irradiation for either Hodgkin’s
lymphoma or breast cancer (even if the heart waspurpo-
sefully blocked or omitted from the treatment
portals [24]), late toxicity is typically manifested as early
or aggravated coronary artery disease [19,25-32]. How-
ever, modern radiation methods have reduced inci-
dences of both acute and late pericardial toxicity [9].
The patient in this case report experienced no acute
toxicity secondary to radiation.
IV. The radiation of cardiac metastases encasing
pacemaker leads has not been previously reported
Until 1978, pacemakers based on bipolar technology
were commonly used, and capable of withstanding
cumulative radiation doses of up to 300 Gy without dys-
function. However, the metal oxide semiconductors of
modern pacemakers render them more sensitive to
radiation[33]. There are only nine reported cases of
radiation-related pacemaker malfunction in the litera-
ture since 1983[33], with widely varying doses of radia-
tion observed to cause pacemaker dysfunction[34,35]. In
one study, 6% of devices showed dysfunction at doses
below 2 Gy [35]. In another study, most devices toler-
ated a cumulative dose of more than 90 Gy before fail-
ing, and only of nineteen studied devices failed with a
cumulative dose of 20 Gy [34]. Either direct or indirect
damage to the circuit (if the pacemaker is out of the
treatment field) by the electromagnetic field is the pro-
posed mechanism of damage. Therefore, while there is
no consensus for a safe threshold of radiation for the
pacemaker within a treatment field, the modern pace-
maker seems relatively resistant to radiation-related mal-
function[34].
For our case subject, the cumulative mean dose to the
pacemaker was 0.2615 Gy with a maximum dose
0.37 Gy. TLDs (thermoluminescent dosimeters) placed
during the first fraction showed the effective dose to the
superior aspect of the pacemaker was (0.862 +/-
0.104 Gy). The treatment plan was modified to ensure
that the cumulative dose to the device itself was less
than 0.50 Gy (0.461 Gy +/- 0.41 Gy). Because of the the-
oretical possibility that treatment response of the tumor
encasing the pacemaker leads could result in a loss of
electrical capture, the pacemaker was interrogated
before and upon completion of every treatment. The
irradiation was carried out under continuous EKG mon-
itoring via transcutaneous pads which could also be
used for external pacing in case of the primary pacer
failure or loss of primary capture.
V. Radiation therapy can successfully palliate cardiac
metastases while preserving quality of life
We decided to treat this patient with IMRT to limit the
cardiac dose and result in less cardiac toxicity. The
patient was treated in a supine position immobilized
with a wing board. A CT simulation with 4D respiratory
gating in 8 phases of respiration was acquired in both
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slice reconstruction and no contrast. The Gross Tumor
Volume (GTV) was defined as the right atrial and right
ventricular tumor. An Internal Tumor Volume (ITV)
(with an additional 1 to 1.5 cm cardiac margin) was
generated from the Maxiumum Intensity Projection
(MIP) using the CT simulation data from all 8 phases of
respiration, taking into account cardiac motion of the
tumor. A Planning Target Volume (PTV) was defined as
the ITV with an additional 5 mm margin in all dimen-
sions. In the free-breathing CT scan, which was used for
the final treatment planning, the lateral left ventricle
and medial left ventricle (including the interventricular
septum) were contoured as avoidance structures. The
patient was treated with an IMRT plan 2.5 Gy per frac-
tion to 87% isodose line delivered in 15 fractions with
8 coplanar beams and 6 mV photons. The actual maxi-
mum dose to the tumor from all beams was 43.1 Gy
(Figure 1). The patient had previously received radiation
to the mediastinum, and his prior treatment plan was
dearchived and reconstructed to avoid overlap of radia-
tion fields and minimize the dose to the lungs. Dosi-
metric paramters are outlined in Table 1.
After completing treatment, the patient did not
experience any significant acute toxicities from the
treatment. He remained exceptionally active until his
death.
VI. Case Summary and Recommendations
We report a successful PET-proven response to IMRT
of a secondary cardiac tumor, which encased the leads
of a dual-chamber pacemaker in a pacer-dependent
patient. The treatment plan was designed to prevent
overlap with the patient’s prior mediastinal radiation
fields, and also to minimize toxicity to the whole heart
and left ventricle. This treatment was well-tolerated by
the patient, with preservation of quality of life.
In their review of secondary cardiac tumors, Cham
et al. suggest that “cardiac metastases should be strongly
suspected in the cancer patient with sudden onset of
unexplained tachycardia, arrhythmia, or congestive heart
failure”[ 3 6 ] .I nt h ea g i n gU Sp o p u l a t i o nw h e r et h eu s e
of permanent pacemakers is increasing[37], cancer
patients with pacemakers will only become more com-
mon. We recommend evaluation for cardiac metastases
in patients with disseminated disease who experience
symptoms of unexplained tachyarrhythmias or other
cardiac abnormalities. Proper cardiac evaluation may be
warranted in these high-risk patients. Traditional onco-
logic staging techniques are generally not adequate for
proper evaluation. For example, the naturally high FDG
uptake of the cardiac muscle on a staging PET/CT scan
may obscure cardiac metastases. As demonstrated by
our case subject, cardiac metastases can be effectively
palliated with radiation therapy to meaningful doses
with limited toxicity using modern techniques. Each
case should be individually evaluated for palliative treat-
ment giving full consideration to the patient’sa n d
family’s goals of care.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompany-
ing images. A copy of the written consent is available
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